Suscribirse

Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients - 30/10/13

Doi : 10.1016/j.jaci.2013.05.039 
Mustafa Yavuz Köker, MD, PhD a, , Yıldız Camcıoğlu, MD b, Karin van Leeuwen, BSc c, Sara Şebnem Kılıç, MD d, Işıl Barlan, MD e, Mustafa Yılmaz, MD f, Ayşe Metin, MD, PhD g, Martin de Boer, BSc c, Hüseyin Avcılar, MD, PhD h, Türkan Patıroğlu, MD i, Alişan Yıldıran, MD j, Olcay Yeğin, MD k, İlhan Tezcan, MD, PhD l, Özden Sanal, MD l, Dirk Roos, PhD c
a Immunology Department and GenKök Laboratory of Immunology, Faculty of Medicine, University of Erciyes, Kayseri, Turkey 
b Pediatric Infectious Diseases, Clinical Immunology and Allergy Division, Cerrahpasa Medical School, University of Istanbul, Istanbul, Turkey 
c Sanquin Research and the Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands 
d Pediatric Immunology Division, Faculty of Medicine, University of Uludağ, Bursa, Turkey 
e Pediatric Allergy and Immunology Division, Faculty of Medicine, University of Marmara, Istanbul, Turkey 
f Pediatric Allergy and Immunology Division, Faculty of Medicine, University of Çukurova, Adana, Turkey 
g Pediatric Immunology Division, Ankara Hematology-Oncology Hospital of Children, Ankara, Turkey 
h Kök Biotek Company, Technocity of University of Erciyes, Kayseri, Turkey 
i Pediatric Hematology and Immunology Division, Faculty of Medicine, University of Erciyes, Kayseri, Turkey 
j Pediatric Allergy and Immunology Division, Faculty of Medicine, University of 19 Mayıs, Samsun, Turkey 
k Pediatric Immunology Division, Faculty of Medicine, University of Akdeniz, Antalya, Turkey 
l Pediatric Immunology Division, Faculty of Medicine, University of Hacettepe, Ankara, Turkey 

Corresponding author: Mustafa Yavuz Köker, MD, PhD, Department of Immunology, Faculty of Medicine, University of Erciyes, Kayseri, Turkey.

Abstract

Background

Chronic granulomatous disease (CGD) is a rare primary immunodeficiency disorder of phagocytes resulting in impaired killing of bacteria and fungi. A mutation in one of the 4 genes encoding the components p22phox, p47phox, p67phox, and p40phox of the leukocyte nicotinamide dinucleotide phosphate reduced (NADPH) oxidase leads to autosomal recessive (AR) CGD. A mutation in the CYBB gene encoding gp91phox leads to X-linked recessive CGD.

Objective

The aim of this study is to show the correlation between clinical, functional, and genetic data of patients with CGD from Turkey.

Methods

We report here the results of 89 patients with CGD from 73 Turkish families in a multicenter study.

Results

Most of the families (55%) have an AR genotype, and 38% have an X-linked genotype; patients from 5 families with a suspected AR genotype (7%) were not fully characterized. We compared patients with CGD according to the severity of NADPH oxidase deficiency of neutrophils. Patients with A220, A670 or X910 phenotypes with a stimulation index of 1.5 or less have early clinical presentation and younger age at diagnosis (mean, 3.2 years). However, in p47phox-deficient cases and in 5 other AR cases with high residual oxidase activity (stimulation index ≥ 3), later and less severe clinical presentation and older age at diagnosis (mean, 7.1 years) were found. Pulmonary involvement was the most common clinical feature, followed by lymphadenitis and abscesses.

Conclusion

Later and less severe clinical presentation and older age at diagnosis are related to the residual NADPH oxidase activity of neutrophils and not to the mode of inheritance. CGD caused by A220 and A670 subtypes manifests as severe as the X910 subtype.

El texto completo de este artículo está disponible en PDF.

Key words : Chronic granulomatous disease, dihydrorhodamine-1,2,3 assay, CYBB, CYBA, NCF1, NCF2, nicotinamide dinucleotide phosphate reduced oxidase, mean fluorescence intensity, stimulation index

Abbreviations used : AR, A22R, CGD, DHR, MFI, NADPH, NBT, phox, PMA, ROI, SI, X-CGD


Esquema


 Supported by TÜBİTAK (the Scientific and Technological Research Council of Turkey), project no. 110S252, and part of the E-Rare program of the European Union.
 Disclosure of potential conflict of interest: M. Y. Köker has received grants, support for travel to meetings for the study or other purposes, and travel/accommodation/meeting expenses from TÜBITAK. Y. Camcioğlu and A. Metin have received grants from TÜBITAK. D. Roos has received a grant from the E-Rare program of the European Union. The rest of the authors declare that they have no relevant conflicts of interest.


© 2013  American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 132 - N° 5

P. 1156 - novembre 2013 Regresar al número
Artículo precedente Artículo precedente
  • Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation
  • Theresa Cole, Mark S. Pearce, Andrew J. Cant, Catherine M. Cale, David Goldblatt, Andrew R. Gennery
| Artículo siguiente Artículo siguiente
  • The long road to optimal management for chronic granulomatous disease
  • Luigi D. Notarangelo

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.